After a first conference day filled with global perspectives and strategic insights, BayOConnect 2025 will turn its focus to concrete innovation drivers on July 2nd: artificial intelligence, start-up momentum, and forward-looking investments will take center stage during the second day of the conference at the Design Offices München Macherei. This international networking conference brings together leading minds from science, industry, technology, and politics to open up new perspectives for the biomedical value chain.
Your last chance to register and become part of the innovation dialogue: www.bayoconnect.org
Artificial Intelligence as a Catalyst for Biomedical Breakthroughs
The second conference day kicks off with Caroline Gubser Keller from Novartis. Following her keynote, the session “Smart Science: A(I)ccelerating Life Sciences” explores how artificial intelligence and deep tech are fundamentally reshaping the innovation potential in life sciences. Moderated by Andreas Schmidt (Springboard Health Angels), representatives from AWS, Google, NVIDIA, Fraunhofer IPA, Helmholtz Munich, The Exploration Company, and Isomorphic Labs will discuss cutting-edge use cases, the technological and regulatory challenges—and outline how AI-based tools can be effectively integrated into research and development.
Start-up Power: New Solutions from the Entrepreneurial Landscape
In the pitch session “Creating New Success Stories” promising start-ups such as BioExoTec, 2NA FISH, Varolis Apimed, Leopard Biosciences, Toleris Biotherapeutics, Tuari Therapeutics, xFOREST, Alithea Biotechnology, MarkHerz, and Berking Theranostics will take the stage. Organized by BioM Biotech Cluster Development and TUM Venture Labs, the session offers insights into current advancements in diagnostics, therapeutics, and platform technologies—fostering connections between young companies, investors, and industry representatives.
Focus on Infectious Diseases: From Reaction to Prevention
Global health crises like the COVID pandemics have highlighted the importance of rapid response capabilities and robust prevention strategies handling infectious diseases. The session “Dealing with Infectious Diseases – Strategies to Prevent Future Outbreaks” brings together experts from Bavarian Nordic, LMU Klinikum München, TUM School of Medicine and Health, Roche Diagnostics, and InflaRx. Under the direction of Prof. Dr. Percy Knolle (TUM), participants will discuss recent advances in pathogen surveillance, vaccine development, and preparedness planning, and prevention and management of future outbreaks by international collaboration and scalable technologies.
Science Meets Capital: Biotech Investment in Transition
Another highlight of the second day is the session “Value-Driven by Design: Aligning Scientific Vision with Investor Expectations.” Representatives from CatalYm, Crelux (a WuXi AppTec company), and Sofinnova Partners will analyze, under the moderation of Enno Spillner (Formycon), how scientific excellence and entrepreneurial expectations can be successfully aligned—a key issue for sustainable innovation and scalable business models.
Awards and Closing Remarks
The day concludes on a celebratory note with the presentation of the BayOConnect Start-up Awards by Santa Munro from the EBD Group.
Following this, the prestigious m⁴ Award ceremony will take place as part of the conference. Once again, five outstanding pre-seed biomedical projects will be honored for their innovation and implementation potential. The subsequent get-together offers participants the opportunity for personal exchange and the deepening of new partnerships.